Bioserv signed a nonexclusive collaboration agreement with Advantar Laboratories to combine each firm’s capabilities for the creation of an improved value chain for client companies.
System will include Affymetrix-validated methods developed on Beckman Coulter’s Biomek FXp Dual Arm Multichannel and span array processing and data generation as well.
Contract will cover activities from cell-line development through to GMP supply.
Combined company will retain Titertek’s Huntsville, AL, facility and Berthold’s German site.
ISCO’s core technology is parthenogenesis, which is not yet approved under NIH’s guidelines for funding hESC (human embryonic stem cell) research.
Electroporation-based cytokine gene therapy is currently in Phase II development against skin cancer.
Passage Bio, a developer of gene therapies for rare monogenic CNS diseases launched five months ago, will partner with Catalent’s Paragon Gene Therapy unit to develop a dedicated manufacturing suite at Paragon’s Harmans, MD, facility.
Viral safety as we know it is batchy, and hence patchy, but it needs to transition to continuous operations, which means that in viral clearance studies, the goal is seamlessness.
Please wait while you are redirected to the right page...